News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Nomination Committee for the 2013 Annual General Meeting in PledPharma AB

December 20, 2012

PledPharma AB
Company Announcement

Nomination Committee for the 2013 Annual General Meeting in PledPharma AB

Stockholm, 2012-12-20 15:01 CET (GLOBE NEWSWIRE) -- In consultation with the
largest shareholders, the Chairman of PledPharma has established a Nomination
Committee for the 2013 Annual General Meeting which is to be held on April 18.
The committee consists of Staffan Persson, Peter Lindell, Gunnar Lindberg and
Håkan Åström (Chairman of PledPharma). Staffan Persson will act as convenor for
the Nomination Committee. 

The Committee's task is to present proposals regarding Chairman and other
members of the board and fees and other remuneration to the Board´s members.
The Nominating Committee shall also submit proposals for appointment and
remuneration of auditors. Further, the Committee shall submit proposals to the
process to appoint the Nomination Committee for the AGM in 2014. 

Shareholders who wish to submit proposals to the Nomination Committee can do so
by e-mail: 

For more information please contact:

Håkan Åström, Chairman

Phone: +46 703 747 213

Jacques Näsström, CEO

Phone: +46 737 130 979

About PledPharma

PledPharma is a Swedish specialty pharma company that develops a new medicine,
PledOx™, for prevention of the severe side effects that patients develop as a
consequence of chemotherapy treatment of cancer. Many times the treatment
cannot be carried out as planned due to very difficult side effects. The
current market for supportive cancer care is some SEK 72 billion. PledOx is a
medicine within the patent protected substance class PLED, which protects the
body’s normal cells against oxidative stress. Oxidative stress is a condition
where an overabundance of harmful oxygen molecules (free oxygen radicals) has
been formed. We are also evaluating opportunities with PLED substances for
other diseases. PledPharma (STO:PLED) is listed on NASDAQ OMX First North. Erik
Penser Bankaktiebolag is the Certified Adviser. For further information, please



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10